Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.64 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161962 | 0.90 | NR3C1 (0.79) | NR3C1PGRNR3C2AR | |
| SCHEMBL1162233 | 0.86 | NR3C1 (0.51) | NR3C1PGRNR3C2AR | |
| SCHEMBL1159726 | 0.85 | NR3C1 (0.68) | NR3C1PGRNR3C2AR | |
| SCHEMBL1162016 | 0.81 | NR3C1 (0.60) | NR3C1PGRNR3C2AR | |
| SCHEMBL1162105 | 0.81 | NR3C1 (0.58) | NR3C1PGRNR3C2AR | |
| SCHEMBL1162064 | 0.81 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL1161588 | 0.81 | NR3C1 (0.63) | NR3C1PGRNR3C2AR | |
| SCHEMBL1161971 | 0.80 | NR3C1 (0.58) | NR3C1PGRNR3C2AR | |
| SCHEMBL1161847 | 0.80 | NR3C1 (0.70) | NR3C1PGRNR3C2AR | |
| SCHEMBL1161756 | 0.80 | NR3C1 (0.82) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220590-A1 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | KAROBIOAB (SE) | 2012-08-30 | — | — | US | disclosed |
| EP-2459524-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011016050-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220590-A1 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 103/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.